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Abstract
Background: Familial Hypercholesterolemia is a common autosomal dominantly inherited disease
that is most frequently caused by mutations in the gene encoding the receptor for low density
lipoproteins (LDLR). Deletions and other major structural rearrangements of the LDLR gene
account for approximately 5% of the mutations in many populations.
Methods:  Five genomic deletions in the LDLR gene were characterized by amplification of
mutated alleles and sequencing to identify genomic breakpoints. A diagnostic assay based on duplex
PCR for the exon 7 – 8 deletion was developed to discriminate between heterozygotes and
normals, and bioinformatic analyses were used to identify interspersed repeats flanking the
deletions.
Results: In one case 15 bp had been inserted at the site of the deleted DNA, and, in all five cases,
Alu elements flanked the sites where deletions had occurred. An assay developed to discriminate
the wildtype and the deletion allele in a simple duplex PCR detected three FH patients as
heterozygotes, and two individuals with normal lipid values were detected as normal homozygotes.
Conclusion: The identification of the breakpoints should make it possible to develop specific tests
for these mutations, and the data provide further evidence for the role of Alu repeats in intragenic
deletions.
Background
Mutations in the LDLR gene are the most frequent cause
of Familial Hypercholesterolemia (FH; Mendelian Inher-
itance in Man (MIM) #143890), an autosomal dominant
condition characterized by elevated concentrations of
LDL in blood plasma. The condition increases the risk of
premature coronary artery disease due to atherosclerosis,
and it occurs in about 1 in 500 in most populations [1].
The mutational spectrum is very heterogeneous in the
Danish and other populations [2,3], including missense
mutations, splice site mutations and large deletions [4].
Major structural rearrangements are usually considered to
account for approximately 5% of mutations [5,6].
Complex rearrangements can be detected by labour-inten-
sive techniques such as Southern blotting followed by
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hybridisation of labelled gene specific probes [7,8], a tech-
nique that requires large amounts of high quality DNA.
We recently showed that Multiplex Ligation-Dependent
Probe Amplification (MLPA) [9], which is based on semi-
quantitative PCR, is a precise and effective diagnostic
method [10] that makes it feasible to screen large num-
bers of patients for mutations of this kind.
Breakpoints have been studied in only a small number of
complex rearrangements, limiting the development of
diagnostic assays to detect specific deletion or duplication
mutations. Ten different LDLR deletions have been iden-
tified in Danish FH patients [2,10-12], and the aim of this
study was to characterize five deletions identified by
MLPA [10] in order to define their exact extent and the
breakpoints of the deletions. The results define the break-
points of each deletion, and they suggest that unequal
homologous recombination due to Alu repeats is respon-
sible for the deletions. We give an example of the develop-
ment of an assay that reproducibly detects the exon 7 – 8
deletion.
Methods
DNA
Genomic DNA was prepared from EDTA-stabilised blood
samples using the PUREGENE Genomic DNA Purification
Kit (Gentra Systems). The study was approved by the
regional ethical committee of Aarhus County. All patients
received informed consent.
Primers and PCR
To characterize the precise locations of the genomic break-
points, we performed a number of amplifications, using
primers located in nearby exons or in bordering introns.
We designed primers based on the genomic sequence
extracted from the Human Genome Browser [13] using
the  LDLR  reference Sequence NM_00527 (May 2004
assembly). PCR was performed using the Expand 20
kbPLUS PCR system (Roche) following the manufacturer's
instructions, except in case of the exon 5 deletion in which
we used the Phusion High-Fidelity DNA Polymerase
(Finnzymes). Primer sequences and annealing tempera-
tures for PCR are shown in Table 1.
PCR products were analysed in 1% agarose gels together
with a normal control sample to confirm amplification of
the expected allele harbouring the deletion of interest. The
relevant PCR fragments were then isolated from the gel,
using the QIAquick gel extraction kit (Qiagen), according
to the manufacturer's instructions, or they were used
directly for further analysis, if there was only one distinct
band. In case of the exon 13 – 15 deletion, PCR was per-
formed using primers amplifying "fragment 5" as
described by others [14] followed by nested PCR using the
isolated amplification product of 8 kilobases as template.
Sequencing
Sequencing was performed using BigDye terminator
chemistry v. 1.1 (Applied Biosystems), using a cycle
sequencing protocol as recommended by the manufac-
turer. Sequencing reactions was ethanol precipitated,
resuspended in HiDi formamide (Applied Biosystems)
and separated on an Applied Biosystems 3130 Genetic
Analyzer or an ABI PRISM 377 Genetic Analyzer (Applied
Biosystems). PCR products were initially sequenced with
the primers used for PCR and later with newly designed
primers in order to obtain the sequence of the breakpoint.
Deletion exon 7 – 8 assay
Duplex PCR to identify the exon 7–8 deletion was per-
formed with specific primers flanking the deletion break-
points: forward: 5'-gaaggcagtggcaagttttc-3' and reverse: 5'-
gtcgatggaaccaagagtgc-3'. In the presence of one mutated
allele, this PCR would normally result in a fragment of
approximately 1.6 kb representing the deletion. To detect
the wildtype allele we added primers amplifying DNA
contained within the deletion breakpoint, thus amplify-
ing only the wildtype allele, using the following primers:
Table 1: Primers for PCR and sequencing
Deletion PCR primers Fragment size* Annealing temperature Sequencing primers
Promoter – exon1 F: gtccgaggaaggtcacagaa
R: cagcacacaaatgaggtggt
3.5 kb 60 R: cagcacacaaatgaggtggt
Exon5 F: gtggtctcggccatccatcc
R: tctgcaagccgcctgcaccg
1.3 kb 72** R: tctgcaagccgcctgcaccg
Exon7 – 8 F: tcctccttcctctctctggc
R: gctgcaggcaggggcgacgc
3 kb 63 R: aaagccaggcacggtggctc
Exon9 – 14 F: ggctacaagtgccagtgtga
R: agctgacctttagcctgacg
2 kb 59 F: tttttgagacagagtctca
R: aaagtccaaaatcaggcc
Exon 13 – 15 F: tctccttatccacttgtgtgtctag
R: gctttggtcttctctgtctttgaat
8 kb 58 F: tagccaggtgtggtggcagg
R: ctgggagtagctaggactgc
F: forward primer, R: reverse primer
* Fragment size for PCR fragment of the mutant allele
** Two-step PCR, 72°C 1:30 min; 98°C 10secBMC Medical Genetics 2006, 7:55 http://www.biomedcentral.com/1471-2350/7/55
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forward: 5'-ggcgaagggatgggtagggg-3' and reverse: 5'-cac-
cactgctgcctgcaagg. The size of the wildtype fragment is
approximately 1.1 kb. Both primer sets were run in one
reaction, using Phusion High-Fidelity DNA Polymerase
(Finnzymes) following the manufacturer's instructions.
Cycling conditions were as follows: initial denaturation at
98°C for 30 seconds, followed by 30 cycles of: 10s at
98°C, 30s at 65°C and 45s at 72°C and, finally, one cycle
of 7 min at 72°C.
Bioinformatic analysis
Sequence traces were aligned to the genomic sequence of
the LDLR gene using SeqScape version 2.5 (Applied Bio-
systems). The genomic sequence used as reference was
taken from the May 2004 assembly in the Human
Genome Browser [13] using the LDLR reference sequence
NM_00527.
For each deletion breakpoint, the neighbouring 150
nucleotides (on each side of the breakpoint) were used to
identify interspersed repeats using RepeatMasker [15],
and they were aligned to the consensus ALU  sequence
described by Deininger and colleagues [16]. The exact
location of the breakpoints was defined using the BLAT
function [13] in the Human Genome Browser, by search-
ing the May 2004 assembly using the sequences obtained
from the amplification products harbouring the deletion
of interest. Comparison of the LDLR sequence to a 15 bp
insertion was performed using BLAST 2 sequences [17].
Results
The data given in Table 2 show that all five probands, each
having one of these deletions, have the characteristic bio-
chemical features of FH, i.e. elevated LDL cholesterol, ele-
vated total cholesterol, and normotriglyceridemia.
Genomic characterization
Primers and annealing temperatures used for PCR are
listed in Table 1, together with approximate fragment
sizes of the mutant PCR fragments and sequencing prim-
ers used to identify the breakpoints. The sequences of
breakpoints and immediate flanking regions are shown in
Figure 1.
Promoter – exon 1 deletion
Initially, we used primers described by Simard et al. [18]
to test whether the deletion involving exon 1 was the same
as the del >15 kb described in the French-Canadian pop-
ulation, and if this was not the case, to determine how
much of the promoter region of the gene was deleted. PCR
amplification did not result in fragments of the expected
size, and primers were therefore designed for an extended
series of amplification reactions. One amplification
resulted in a fragment of approximately 3.5 kb. This frag-
ment was sequenced directly using new internal primers.
The deletion breakpoint revealed a segment of 9 identical
bases in the upstream breakpoint and the downstream
breakpoint (see Figure 1), and was surrounded by a high
degree of sequence similarity (data not shown). The
breakpoint was flanked by Alu repeats (Table 3).
Exon 5 deletion
Primers in exon 4 and exon 6 were used to amplify the
deletion affecting exon 5. The resulting fragment of
approximately 1.3 kb was sequenced with the reverse
primer used for PCR and revealed the deletion break-
point. Sequence data were compared to data concerning
Table 2: Clinical characteristics of index patients with deletions in the LDLR gene
Deletion Total cholesterol (mmol/l) LDL cholesterol (mmol/l) Triglycerides (mmol/l)
Promoter – exon1 13.0 10.4 1.7
exon 5 10.6 9.1 2.3
exon 7 – exon 8 16.0 13.9 1.5
Exon 9 – exon 14 9.1 NA NA
Exon 13 – exon 15 8.9 7.3 1.5
Values are means of two measurements when available. NA: data not available
Table 3: Genomic characteristics of deletion breakpoints in the LDLR gene
Deletion Deletion size, bp 5' breakpoint 3' breakpoint Repetitive element 5' Repetitive element 3'
Promoter – exon1 9325 11054981 11064306 Alu Y Alu Sq
Exon5 1042 11077854 11078895 Alu Sx Alu Jo
Exon7 – 8 3012 11081462 11084473 Alu Sg/x Alu Sg/x
Exon9 – 14 9713 11084618 11094330 Alu Sq Alu Sq
Exon 13 – 15 6298 11090883 11097180 Alu Sg/X Alu Sg/x
Breakpoint locations are based on the May 2004 assembly extracted from the Human Genome Browser [13]BMC Medical Genetics 2006, 7:55 http://www.biomedcentral.com/1471-2350/7/55
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Sequence data of deletions in the LDLR gene Figure 1
Sequence data of deletions in the LDLR gene. Boxed sequence represents sequence overlap between the 5' end and the 3' end 
of the reference sequence. Arrows represent the limits of the normal intronic sequence on each side of the breakpoint. A) 
Promoter – exon 1 deletion. B) Exon 5 deletion. C) Exon 7 – 8 deletion. D) Exon 9 – 14 deletion and E) Exon 13 – 15 deletion, 
in which the dotted red box indicates a 15 basepair insertion.
upstream from exon 1 and promoter intron 1
A
intron 4 intron 5
B
intron 6 intron 8
C
D
intron 8 intron 14
E
intron 12 intron 15
insertionBMC Medical Genetics 2006, 7:55 http://www.biomedcentral.com/1471-2350/7/55
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an exon 5 deletion in a Danish FH patient that we pub-
lished several years ago [11]. The comparison indicated
that the two deletions were the same.
Exon 7 – 8 deletion
PCR with primers located in exon 6 and exon 9 revealed a
PCR product of 3 kb. Sequence analysis using a primer in
intron 8 revealed a breakpoint with an 8 bp overlap. The
sequence flanking the breakpoint was classified as Alu Sg/
x in both the 5' and 3' end, with a high degree of sequence
identity. A schematic representation of the deletion is
given in Figure 2.
Exon 9 – 14 deletion
The mutated allele, predicted to delete 6 exons, was iso-
lated from a PCR fragment of approximately 2 kb. The
breakpoint was revealed using two sequencing primers,
one located in intron 8 and one located in intron 14. It
was flanked by Alu  Sq repeats, and the overlapping
sequence represents the major part of the ALU-DEIN con-
sensus sequence proposed to be a recombinogenic
hotspot [19].
Exon 13 – 15 deletion
Using the method described by Kim et al [14], we ampli-
fied a fragment of 8 kb. Sequencing of a PCR fragment,
generated by nested PCR using the sequencing primers
(Table 1), resulted in bi-directional sequence data show-
ing that the deletion of 6.3 kb was accompanied by an
insertion of 15 bp (Figure 1). The deletion was flanked by
two Alu Sg/x elements, and the short insertion did not
show similarity to any interspersed repeats or low com-
Schematic representation of the mutation deleting exon 7 and 8 of the LDLR gene Figure 2
Schematic representation of the mutation deleting exon 7 and 8 of the LDLR gene. The locations of the primers used for the 
diagnostic duplex PCR is shown. Deletion breakpoints are flanked by Alu Sg/x elements (grey boxes). The box in the sequence 
data represents nucleotides present in each end of the breakpoint of the reference sequence shown below the sequence trace.
Exon 6 Exon 7 Exon 8 Exon 9 Exon 10 Alu Sg/x Alu Sg/x
Exon 6 Exon 9 Exon 10 Alu Sg/x
3 kb deletion of exon 7 and 8
ggttcactgcaacctccacctaccaggttcaagcaa... 3 kb ...cacctcccaggttccagcaattctcctgcctc
Wildtype fragment 1.1 kb
Deletion fragment 1.6 kbBMC Medical Genetics 2006, 7:55 http://www.biomedcentral.com/1471-2350/7/55
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plexity DNA sequences, or to any other DNA sequence in
the LDLR gene.
Diagnostic assay for the exon 7–8 deletion
In order to be able to discriminate the two alleles in a fam-
ily segregation for the exon 7 – 8 deletion, an assay was
developed, based on duplex PCR amplifying the deletion
allele, and the wildtype allele, by using two different
primer pairs giving amplification products of similar size
to ensure reproducible detection of both alleles. The loca-
tion of the primers is shown in figure 2. As evident from
Figure 3, the assay detected both the deletion and the
wildtype allele in three hyperlipidemic subjects, classify-
ing them as heterozygotes, while in two normal subjects
only the wildtype specific fragment of 1.1 kb was ampli-
fied, showing that these were homozygous wildtypes.
Discussion
In this work we describe the breakpoints of five deletions
found in a Danish sample of FH patients, in which SSCP
and sequencing failed to detect mutations in the LDLR
gene [10]. The proportion of FH cases caused by large rear-
rangements has been estimated to be approximately 5%
[5]. The number of large rearrangements reported to the
FH website [4] was 92, however, accounting for 13.5% of
the mutations in the database. The five deletions
described in this paper account for 3.1% of the mutations
identified in Danish FH mutation carriers [10], whereas a
recent study of a Norwegian population of FH patients
show that 10.2% of them carry complex rearrangements
due to deletions or duplications in the LDLR [20]. A Cana-
dian study detected 17% deletions in a sample of 70 FH
patients [21]. Complex rearrangements thus account for a
small but possibly quite variable proportion of LDLR
mutations in different populations.
The MLPA method initially used to identify the deletions
described here does not include the promoter, exon 10 or
exon 13 of the LDLR gene. Rearrangements involving only
exon 10, exon 13 or the promoter will therefore not be
diagnosed using MLPA. We expanded the findings made
by MLPA in the two cases (del prom – exon 1 and del 13
– 15 respectively) in which it was unclear whether the
deletion included parts of the promoter or exon 13. We
found that the exon 1 deletion included a large part of the
sequence upstream of exon 1, including the promoter,
most probably rendering this a null allele. In the case of
the deletion involving exon 14 and 15, the results show
that exon 13 was also deleted. A new version of the MLPA
kit now includes exon 10 and 13, making findings in these
regions of the gene more reliable. On the other hand, if
the MLPA method detects a mutation causing only a dele-
tion of one exon, it could possibly be a false positive
result, due to the risk of failure to bind or inefficient bind-
ing of a single probe to the sample DNA. MLPA results
indicating a one-exon deletion should therefore always be
confirmed by an independent method.
Three other deletions involving the promoter and exon 1
have been identified previously [4], one of which was
characterized recently by Canadian researchers [18]. We
show that the deletion found in our patient was not iden-
tical to the one found in Canada. The deletion that we
found was located approximately 6.1 kb upstream and 3
kb downstream of exon 1, whereas the French-Canadian
deletion was located 11.7 kb upstream and 4 kb down-
stream of exon 1.
Three rearrangements deleting only exon 5 have been
described earlier [8,11,22], two of them apparently
smaller than the one described here. We found that the
exon 5 deletion was identical to the one we have described
Assay to detect the exon 7 – 8 deletion Figure 3
Assay to detect the exon 7 – 8 deletion. The pedigree illus-
trates the five individuals available (ID03, ID01, ID04, ID07 
and ID08). Symbols with two black triangles represent indi-
viduals with hyperlipidemia and coronary artery disease 
(CAD), while open symbols represent individuals with nor-
mal lipid values and no CAD symptoms. The index patient 
ID01 is marked with an arrow. The left lane of the gel is a 
size marker, while the following lanes are the result of the 
duplex PCR of the individual above. In the normal individuals 
ID03 and ID08, only one fragment of 1.1 kb is amplified, indi-
cating homozygosity for the normal allele. In the affected 
individiuals ID01, ID04 and ID07 two fragments of 1.6 and 
1.1 kb is amplified, indicating heterozygosity for the mutation 
represented by the 1.6 kb fragment.
ID 03
ID 07
ID 08
ID 04
ID 01BMC Medical Genetics 2006, 7:55 http://www.biomedcentral.com/1471-2350/7/55
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earlier [11]. Deletions involving exon 7 – 8 and exon 13 –
15 have also been seen in other populations [4], but lack
of information on precise breakpoints makes it impossi-
ble to establish whether the deletions we describe are
identical to the ones reported from other populations.
Mutations deleting exon 9 to 14 have to our knowledge
not been identified in other populations. The diagnostic
assay set up to detect the exon 7 – 8 deletion (Figure 3)
proved to be a valuable and simple means of detecting
affected family members. Instead of developing an assay
based on ordinary long range PCR, e.g. detecting a frag-
ment of 4.6 kb representing the wildtype allele and a frag-
ment of 1.6 kb representing the mutated allele, we used
duplex PCR, with one set of primers outside the break-
point detecting the mutated allele, and another set of
primers within the deletion breakpoints detecting the
wildtype allele, to get amplification products of similar
size. We were therefore able to run the PCR under rela-
tively stringent conditions to get clear and reproducible
bands from both the wildtype and mutated allele.
Since the first deletions in the LDLR gene were described
in 1985 [7,23] it has been widely accepted that complex
rearrangements can be ascribed to an abundance of Alu
repeats in the gene, since unequal homologous recombi-
nation occurs fairly easily between two Alu elements, typ-
ically located in different introns [24]. Alu  sequences
represent as much as 85% of the intronic sequences of the
LDLR gene [25]. The five deletions described in this work
are all flanked by Alu elements, supporting a mutation
mechanism involving unequal homologous recombina-
tion between highly similar Alu elements. Rüdiger and
colleagues [19] suggested that a 26 basepair part of an Alu
consensus sequence (ALU-DEIN) served as a recombino-
genic hotspot, not only because it occurs close to several
complex rearrangements in the LDLR and other genes, but
also because it contains a motif known to mediate recom-
bination in Escherichia coli. The ALU-DEIN sequence was
also present in the exon 5 deletion identical to the one
described here; it occurs close to the 5' flank of the pro-
moter – exon 1 deletion; and it constitutes the major part
of the overlapping sequence in the exon 9 – 14 deletion.
Recently the hypothetical recombinogenic hotspot was
also suggested to explain the occurrence of two deletions
in the ALD  gene [26], lending further support to the
hypothesis that the ALU-DEIN sequence is a recombino-
genic hotspot that can cause unequal homologous recom-
bination.
Conclusion
In conclusion, the present study defines the precise
genomic breakpoints of five deletions in the LDLR gene,
opening new possibilities to develop specific diagnostic
tests for these deletions. Furthermore, it supports the
proposition that Alu repeats are involved in mutational
events in the LDLR.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
PHN designed the study, performed bioinformatic stud-
ies, participated in the interpretation of the data and
drafted the manuscript. DD participated in the design of
the study and helped to draft the manuscript. AS and GGN
carried out molecular genetic studies and participated in
the interpretation of the data. OF selected and evaluated
patients and helped to draft the manuscript. MLN selected
and evaluated patients. All authors read and approved the
final manuscript.
Acknowledgements
The work was supported by the Beckett foundation and director Kurt Bøn-
nelycke og hustru Grethe Bønnelyckes foundation. We are grateful to the 
skilful technical assistance from Mrs Kirsten Kruse Olsen and Mrs Kirsten 
Hald.
References
1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG:
Hyperlipidemia in coronary heart disease. II: Genetic analy-
sis of lipid levels in 176 families and delineation of a new
inherited disorder, combined hyperlipidemia.  J Clin Invest
1973, 52:1544-68.
2. Jensen HK, Jensen LG, Meinertz H, Hansen PS, Gregersen N, Faerge-
man : Spectrum of LDL receptor gene mutations in Den-
mark: implications for molecular diagnostic strategy in
heterozygous familial hypercholesterolemia.  Atherosclerosis
1999, 146:337-44.
3. Dedoussis GV, Schmidt H, Genschel J: LDL-receptor mutations in
Europe.  Hum Mutat 2004, 24:443-59.
4. Heath KE, Gahan M, Whittall RA, Humphries SE: Low-density lipo-
protein receptor gene (LDLR) world-wide website in familial
hypercholesterolaemia: update, new features and mutation
analysis.  Atherosclerosis 2001, 154:243-6 [http://www.ucl.ac.uk/fh].
5. Sun XM, Webb JC, Gudnason V, Humphries S, Seed M, Thompson
GR, Knight BL, Soutar AK: Characterization of deletions in the
LDL receptor gene in patients with familial hypercholester-
olemia in the United Kingdom.  Arterioscler Thromb 1992,
12:762-70.
6. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP:
The molecular basis of familial hypercholesterolemia in The
Netherlands.  Hum Genet 2001, 109:602-15.
7. Lehrman MA, Schneider WJ, Sudhof TC, Brown MS, Goldstein JL,
Russell DW: Mutation in LDL receptor: Alu-Alu recombina-
tion deletes exons encoding transmembrane and cytoplas-
mic domains.  Science 1985, 227:140-6.
8. Hobbs HH, Brown MS, Goldstein JL, Russell DW: Deletion of exon
encoding cysteine-rich repeat of low density lipoprotein
receptor alters its binding specificity in a subject with familial
hypercholesterolemia.  J Biol Chem 1986, 261:13114-20.
9. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F,
Pals G: Relative quantification of 40 nucleic acid sequences by
multiplex ligation-dependent probe amplification.  Nucleic
Acids Res 2002, 30:e57.
10. Damgaard D, Nissen PH, Jensen LG, Nielsen GG, Stenderup A,
Larsen ML, Faergeman O: Detection of large deletions in the
LDL receptor gene with quantitative PCR methods.  BMC
Med Genet 2005, 6:15.
11. Rudiger NS, Hansen PS, Jorgensen M, Faergeman O, Bolund L,
Gregersen N: Repetitive sequences involved in the recombi-
nation leading to deletion of exon 5 of the low-density-lipo-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2006, 7:55 http://www.biomedcentral.com/1471-2350/7/55
Page 8 of 8
(page number not for citation purposes)
protein receptor gene in a patient with familial
hypercholesterolemia.  Eur J Biochem 1991, 198:107-11.
12. Brusgaard K, Jordan P, Hansen H, Hansen AB, Horder M: Molecular
genetic analysis of 1053 Danish individuals with clinical signs
of familial hypercholesterolemia.  Clin Genet 2006, 69:277-83.
13. Kent JW: BLAT – The BLAST Like Alignment Tool.  Genome
Res 2002, 12:656-664 [http://genome.ucsc.edu/].
14. Kim SH, Bae JH, Chae JJ, Kim UK, Choe SJ, Namkoong Y, Kim HS,
Park YB, Lee CC: Long-distance PCR-based screening for large
rearrangements of the LDL receptor gene in Korean
patients with familial hypercholesterolemia.  Clin Chem 1999,
45:1424-30.
15. Smit AFA, Hubley R, Green P: RepeatMasker Open-3.0.  Unpub-
lished :1996-2004 [http://www.repeatmasker.org].
16. Deininger PL, Jolly DJ, Rubin CM, Friedmann T, Schmid CW: Base
sequence studies of 300 nucleotide renatured repeated
human DNA clones.  J Mol Biol 1981, 151:17-33.
17. Tatusova TA, Madden TL: Blast 2 sequences – a new tool for
comparing protein and nucleotide sequences.  FEMS Microbiol
Lett 1999, 174:247-250 [http://www.ncbi.nlm.nih.gov/blast/bl2seq/
wblast2.cgi].
18. Simard LR, Viel J, Lambert M, Paradis G, Levy E, Delvin EE, Mitchell
GA:  The Delta>15 Kb deletion French Canadian founder
mutation in familial hypercholesterolemia: rapid polymer-
ase chain reaction-based diagnostic assay and prevalence in
Quebec.  Clin Genet 2004, 65:202-8.
19. Rudiger NS, Gregersen N, Kielland-Brandt MC: One short well
conserved region of Alu-sequences is involved in human
gene rearrangements and has homology with prokaryotic
chi.  Nucleic Acids Res 1995, 23:256-60.
20. Holla OL, Teie C, Berge KE, Leren TP: Identification of deletions
and duplications in the low density lipoprotein receptor gene
by MLPA.  Clin Chim Acta 2005, 356:164-71.
21. Wang J, Ban MR, Hegele RA: Multiplex ligation-dependent probe
amplification of LDLR enhances molecular diagnosis of
familial hypercholesterolemia.  J Lipid Res 2005, 46:366-72.
22. Horsthemke B, Dunning A, Humphries S: Identification of dele-
tions in the human low density lipoprotein receptor gene.  J
Med Genet 1987, 24:144-7.
23. Horsthemke B, Kessling AM, Seed M, Wynn V, Williamson R, Hum-
phries SE: Identification of a deletion in the low density lipo-
protein (LDL) receptor gene in a patient with familial
hypercholesterolaemia.  Hum Genet 1985, 71:75-8.
24. Deininger PL, Batzer MA: Alu Repeats and Human Disease.  Mol
Genet Metab 1999, 67:183-193.
25. Amsellem S, Briffaut D, Carrie A, Rabes JP, Girardet JP, Fredenrich A,
Moulin P, Krempf M, Reznik Y, Vialettes B, de Gennes JL, Brukert E,
Benlian P: Intronic mutations outside of Alu-repeat-rich
domains of the LDL receptor gene are a cause of familial
hypercholesterolemia.  Hum Genet 2002, 111:501-10.
26. Kutsche K, Ressler B, Katzera HG, Orth U, Gillessen-Kaesbach G,
Morlot S, Schwinger E, Gal A: Characterization of breakpoint
sequences of five rearrangements in L1CAM and ABCD1
(ALD) genes.  Hum Mutat 2002, 19:526-35.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/7/55/prepub